Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 28, 2015 4:34 AM ET


Company Overview of ALPHAEON Corporation

Company Overview

ALPHAEON Corporation provides beauty, wellness, and lifestyle products in the United States. It offers age defense creams for dry, normal, and combination skin; and revitalizing concentrate serums, face and eyes cleansing solutions, skin radiance smoothing creams, and deep repair soothing balms. The company offers skin care assessment solutions; credit cards that provide financing options for individuals; and PRN (Physician Recommended Nutriceuticals) products, which include omega-3 EPA and vitamin D3 soft-gels; omega-3 EPA and vitamin D3 liquids; macular vitamins; and custom-formulated omega-3 EPA, vitamin D3, and carotenoids soft-gels for dry eyes. It also helps patients to find physicians...

18191 Von Karman Avenue

Suite 500

Irvine, CA 92612

United States

Founded in 2012



Key Executives for ALPHAEON Corporation

Chief Executive Officer and Director
Age: 45
President and Chief Operating Officer
Chief Financial Officer
Age: 56
President of Americas
President of Asia Pacific
Compensation as of Fiscal Year 2015.

ALPHAEON Corporation Key Developments

ALPHAEON Corporation Unveils TouchMD® Platform

ALPHAEON Corporation announced they are unveiling the new TouchMD® platform at the annual American Society of Aesthetic Plastic Surgeons meeting in Montreal. TouchMD version 4 brings a full redesign of the patient consultation platform, with an enhanced visual experience through new layouts that showcase practice content and maximize screen space, intuitive navigation allowing for quick access to all images and content, built-in advanced drawing tools, and the ability to brand and customize the platform for each practice. Version 4 also includes a modern redesign of myTouchMD, the consumer portal.

ALPHAEON Corporation Appoints Jeff Castillo as President of the Americas, and Kuntal Joshi as President of Asia Pacific

ALPHAEON Corporation announced that Jeff Castillo has joined the organization as President of the Americas, and Kuntal Joshi has joined as President of Asia Pacific. Mr. Castillo and Mr. Joshi each bring more than 25 years of experience in the medical device sector to their roles at the company. Mr. Castillo was most recently a Divisional Vice President at Abbott Medical Optics (AMO) where he focused on leading the Americas organization to double-digit growth through greater alignment and focus on customer needs and market dynamics. While at AMO, Jeff was responsible for deploying a customer focused strategy concentrating on strengthening AMO's value proposition through the creation of new services, launching value added products, and maximizing the portfolio. Prior to AMO, Mr. Castillo spent 22 years at Johnson & Johnson, where he held a variety of senior commercial positions based in the U.S. and Latin America. Prior to joining ALPHAEON, Mr. Joshi spent the last 12 years in the Asia Pacific Region.

FDA Accepts Investigational New Drug Application for ALPHAEON's Neurotoxin EVOSYAL

ALPHAEON(R) Corporation, subsidiary of Strathspey Crown Holdings LLC, announced that the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application to conduct clinical studies for EVOSYAL(TM), an advanced Botulinum toxin Type A neurotoxin that was acquired by ALPHAEON last October, as part of the acquisition of Evolus Inc. According to the ASPS(R), Botulinum toxin Type A was injected for cosmetic purposes more than 6 million times last year, accounting for over 2 billion dollars of consumer spend annually, which was a 3% increase from the previous year. ALPHAEON expects the initial clinical trial to be fully enrolled by the end of 2014.

Similar Private Companies By Industry

Company Name Region
Marketing Representatives, Inc. United States
Philips Accessories & Computers Peripherals, Inc. United States
United Stationers Receivables, LLC United States
Dave's Design Center, Inc. United States
Builders Lighting & Hardware Inc. United States

Recent Private Companies Transactions

Private Placement
January 14, 2015
September 8, 2014
Clarion Medical Technologies Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALPHAEON Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at